A Shot That Rebuilds Joints
A research team at the University of Colorado Boulder has developed a suite of experimental osteoarthritis therapies that can regenerate damaged joints rather than merely relieve pain — with a single injection restoring arthritic joints to a healthy state within weeks in animal studies.
The breakthrough comes from the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, the inaugural initiative of the Advanced Research Projects Agency for Health (ARPA-H). The team has now advanced to phase two of the up to $33.5 million project, bringing human clinical trials into view by 2028.
"In two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals," said lead principal investigator Stephanie Bryant, professor of chemical and biological engineering at CU Boulder.
The Scale of the Problem
Osteoarthritis is the third most common disease in the United States, affecting roughly one in six people over age 30 worldwide. It causes cartilage — the cushioning tissue that prevents bones from grinding together — to progressively decay. Over time, it damages bone as well, reshaping joints and making movement excruciating.
Currently, patients face a stark choice: manage the pain or undergo joint replacement surgery. There is no cure.
Two Approaches
The Colorado team is pursuing two complementary strategies:
Regenerative Injection: The centerpiece of the research is a patented drug-delivery system that can be injected directly into the joint. It releases intermittent bursts of a repurposed FDA-approved drug over months, coaxing the body's own repair mechanisms to rebuild cartilage and bone. In animal studies, arthritic joints returned to a healthy state within four to eight weeks.
Biomaterial Repair Kit: For patients with significant cartilage or bone lesions, the team developed a cocktail of engineered proteins that can be injected arthroscopically and cured into place. This acts as a scaffold that recruits the body's own progenitor cells to patch the damage, achieving "full regeneration and repair of the defect."
Human Trials on the Horizon
The ARPA-H NITRO program was created specifically to develop "minimally invasive therapeutics that fully regenerate damaged joints." With phase one successfully completed, the team is now advancing toward phase two — preclinical optimization and safety studies required before human trials.
The team has formed a company, Renovare Therapeutics Inc., to move toward commercialization. If future studies go according to plan, Bryant anticipates clinical trials could begin within 18 months.
"This could be a real game-changer for patients," said Bryant.
Dr. Evalina Burger, chair of orthopedics at CU Anschutz, highlighted the human impact: "At the moment, the options for many patients are either a massive, expensive surgery or nothing. There's not a lot in between."
The research represents a fundamental shift in how osteoarthritis could be treated — not as a chronic condition to be managed, but as a reversible disease. If the approach translates to humans, it could transform the lives of the estimated 500 million people worldwide living with osteoarthritis.
